Jason Gerberry
Stock Analyst at B of A Securities
(3.76)
# 705
Out of 4,876 analysts
155
Total ratings
55.45%
Success rate
5.71%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Buy | $25 → $23 | $12.83 | +79.27% | 2 | Jun 11, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $45 → $46 | $43.09 | +6.75% | 3 | Jun 5, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $20 → $22 | $16.56 | +32.85% | 14 | May 8, 2025 | |
| PCVX Vaxcyte | Maintains: Buy | $157 → $137 | $32.88 | +316.67% | 9 | Apr 1, 2025 | |
| IMVT Immunovant | Maintains: Buy | $38 → $33 | $16.39 | +101.34% | 5 | Mar 20, 2025 | |
| VTRS Viatris | Maintains: Underperform | $11 → $10 | $9.12 | +9.65% | 3 | Feb 28, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $143 → $167 | $102.57 | +62.82% | 5 | Feb 11, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Buy | $30 | $21.89 | +37.05% | 2 | Jan 9, 2025 | |
| ACLX Arcellx | Maintains: Buy | $84 → $100 | $64.77 | +54.39% | 4 | Nov 6, 2024 | |
| BHVN Biohaven | Maintains: Buy | $52 → $62 | $14.74 | +320.62% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $3.32 | +622.89% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $3 | $0.72 | +315.00% | 3 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $68 | $39.78 | +70.94% | 5 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $20 | $19.48 | +2.67% | 3 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $41 → $31 | $28.07 | +10.44% | 6 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $600 → $550 | $13.38 | +4,010.61% | 3 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $29 | $28.83 | +0.59% | 9 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $37 | $16.07 | +130.24% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $32.20 | +73.91% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $30 | $31.86 | -5.84% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $63 | $23.18 | +171.79% | 1 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $204 → $217 | $107.59 | +101.69% | 5 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $100 → $50 | $5.30 | +843.40% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $450 → $500 | $795.12 | -37.12% | 15 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $1.20 | +650.00% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $9.98 | +150.50% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $2.52 | +98.41% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $6.41 | +321.22% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $0.73 | +2,630.00% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $10 | $0.58 | +1,616.74% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $186.79 | -49.14% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $46.65 | +28.62% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $37 | $24.24 | +52.64% | 4 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $78.83 | +14.17% | 11 | Oct 17, 2019 |
Liquidia
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $12.83
Upside: +79.27%
Exelixis
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $43.09
Upside: +6.75%
Teva Pharmaceutical Industries
May 8, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $16.56
Upside: +32.85%
Vaxcyte
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $32.88
Upside: +316.67%
Immunovant
Mar 20, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $16.39
Upside: +101.34%
Viatris
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $9.12
Upside: +9.65%
Axsome Therapeutics
Feb 11, 2025
Maintains: Buy
Price Target: $143 → $167
Current: $102.57
Upside: +62.82%
Catalyst Pharmaceuticals
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $21.89
Upside: +37.05%
Arcellx
Nov 6, 2024
Maintains: Buy
Price Target: $84 → $100
Current: $64.77
Upside: +54.39%
Biohaven
Sep 24, 2024
Maintains: Buy
Price Target: $52 → $62
Current: $14.74
Upside: +320.62%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $3.32
Upside: +622.89%
Sep 4, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.72
Upside: +315.00%
Jul 23, 2024
Maintains: Buy
Price Target: $67 → $68
Current: $39.78
Upside: +70.94%
Jun 11, 2024
Maintains: Buy
Price Target: $21 → $20
Current: $19.48
Upside: +2.67%
Apr 1, 2024
Downgrades: Underperform
Price Target: $41 → $31
Current: $28.07
Upside: +10.44%
Mar 25, 2024
Maintains: Buy
Price Target: $600 → $550
Current: $13.38
Upside: +4,010.61%
Jan 2, 2024
Maintains: Neutral
Price Target: $27 → $29
Current: $28.83
Upside: +0.59%
Jan 2, 2024
Maintains: Buy
Price Target: $29 → $37
Current: $16.07
Upside: +130.24%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $32.20
Upside: +73.91%
Jan 2, 2024
Downgrades: Underperform
Price Target: $30
Current: $31.86
Upside: -5.84%
Nov 17, 2023
Initiates: Neutral
Price Target: $63
Current: $23.18
Upside: +171.79%
Aug 10, 2023
Maintains: Buy
Price Target: $204 → $217
Current: $107.59
Upside: +101.69%
Aug 8, 2023
Downgrades: Underperform
Price Target: $100 → $50
Current: $5.30
Upside: +843.40%
May 24, 2023
Maintains: Buy
Price Target: $450 → $500
Current: $795.12
Upside: -37.12%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $1.20
Upside: +650.00%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $9.98
Upside: +150.50%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $2.52
Upside: +98.41%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $6.41
Upside: +321.22%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $0.73
Upside: +2,630.00%
Jul 15, 2020
Downgrades: Neutral
Price Target: $17 → $10
Current: $0.58
Upside: +1,616.74%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $186.79
Upside: -49.14%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $46.65
Upside: +28.62%
Oct 17, 2019
Reinstates: Neutral
Price Target: $37
Current: $24.24
Upside: +52.64%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $78.83
Upside: +14.17%